Tribendimidine
Tribendimidine[edit]
Tribendimidine is an anthelmintic agent used primarily in the treatment of parasitic worm infections. It is particularly effective against Ascaris lumbricoides, hookworm, and Enterobius vermicularis. Tribendimidine is a derivative of amidantel and was developed in China as a broad-spectrum anthelmintic.
Mechanism of Action[edit]
Tribendimidine works by targeting the neuromuscular junction of the parasites. It acts as an agonist at the nicotinic acetylcholine receptors, causing spastic paralysis of the worms. This paralysis prevents the worms from maintaining their position in the host's intestine, leading to their expulsion through normal peristaltic action.
Pharmacokinetics[edit]
After oral administration, tribendimidine is rapidly absorbed and metabolized. The drug is converted into its active metabolite, p-hydroxy tribendimidine, which is responsible for its anthelmintic activity. The elimination of the drug and its metabolites occurs primarily through the renal system.
Clinical Use[edit]
Tribendimidine is used in the treatment of several helminth infections:
It is often administered as a single oral dose, which is effective in clearing the infection in most cases. The drug is well-tolerated, with minimal side effects reported.
Side Effects[edit]
Common side effects of tribendimidine include mild gastrointestinal disturbances such as nausea and abdominal pain. These side effects are generally transient and resolve without intervention.
Development and Approval[edit]
Tribendimidine was developed in China and has been used extensively in national deworming programs. Its development was part of an effort to find effective treatments for parasitic infections that are prevalent in many developing countries.
